Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | KarMMA study shows improved QoL in patients with R/R multiple myeloma treated with ide-cel

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses findings from the Phase II KarMMa study (NCT03361748), which investigated the impact of treatment with idecabtagene vicleucel (ide-cel), a BCMA-targeting CAR-T cell therapy, in patients with heavily pretreated multiple myeloma (MM). Prof. Delforge briefly describes the study methods and highlights the impact of ide-cel on patients’ quality of life (QoL), which was found to significantly improve physical and emotional wellbeing and reduce disease-related symptoms. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.